Epilepsia 1989-01-01

Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome.

Index: Epilepsia 30(4) , 422-9, (1989)

Full Text: HTML

Abstract

This study evaluated the effects of cinromide in patients with Lennox-Gastaut Syndrome. No difference between cinromide and placebo was shown in terms of seizure reduction or global evaluations. This study is important, however, because it represents an effort to overcome methodologic difficulties inherent in evaluating this population, and because a substantial placebo response was demonstrated. The need for well-designed, placebo-controlled clinical studies of potential antiepileptic drugs, even in an especially refractory and mentally impaired population, is underscored by the study's outcome.


Related Compounds

Related Articles:

Prediction of steady-state behavior of metabolite from dosing of parent drug.

1980-05-01

[J. Pharm. Sci. 69(5) , 610-2, (1980)]

Variability in the determination of fraction metabolized in a triangular metabolic problem and its resolution with stable isotope methodology.

1984-02-01

[J. Pharm. Sci. 73(2) , 285-7, (1984)]

Simultaneous determination of the anticonvulsants, cinromide (3-bromo-n-ethylcinnamamide), 3-bromocinnamamide, and carbamazepine in plasma by high-performance liquid chromatography.

[J. Chromatogr. A. 163(2) , 187-93, (1979)]

The effect of cinromide on "kindled" seizures in the rat.

1982-03-01

[Neuropharmacology 21(3) , 273-6, (1982)]

Fractions metabolized in a triangular metabolic system: cinromide and two metabolites in the rhesus monkey.

1985-08-01

[J. Pharmacokinet. Biopharm. 13(4) , 373-86, (1985)]

More Articles...